Nektar Therapeutics (NASDAQ:NKTR) Shorted Shares Increased 6.27% After Market Selling

July 18, 2017 - By Louis Casey

 Nektar Therapeutics (NASDAQ:NKTR) Shorted Shares Increased 6.27% After Market Selling

Investors sentiment increased to 2.42 in Q4 2016. Its up 1.13, from 1.29 in 2016Q3. It increased, as 22 investors sold Nektar Therapeutics shares while 28 reduced holdings. 33 funds opened positions while 88 raised stakes. 141.64 million shares or 8.47% more from 130.58 million shares in 2016Q3 were reported.
Blackrock Fund has invested 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Td Asset Management Inc holds 0% or 17,900 shares. Products Partners Ltd Liability Corporation owns 246,199 shares. Parkside State Bank & Tru accumulated 0% or 91 shares. Us Fincl Bank De stated it has 0% in Nektar Therapeutics (NASDAQ:NKTR). Prudential has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR). Tocqueville Asset Limited Partnership invested 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Plante Moran Financial Advisors Ltd Com owns 102 shares for 0% of their portfolio. Westfield Capital Comm Limited Partnership holds 0.45% in Nektar Therapeutics (NASDAQ:NKTR) or 4.19M shares. Landscape Capital Mgmt Limited Liability Company stated it has 15,584 shares. Primecap Management Ca owns 0.26% invested in Nektar Therapeutics (NASDAQ:NKTR) for 21.44M shares. Sei Invests Company has invested 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Cibc Asset Inc has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 10,366 shares. Ubs Asset Americas Inc owns 94,854 shares. Allianz Asset Mgmt Ag has 111,217 shares.

Since February 2, 2017, it had 0 buys, and 26 selling transactions for $17.12 million activity. $3.03M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Labrucherie Gil M on Thursday, March 2. Doberstein Stephen K also sold $2.17 million worth of Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, April 5. The insider KUEBLER CHRISTOPHER A sold $328,200. $19,145 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Gergel Ivan P.. Lingnau Lutz sold 30,000 shares worth $392,400. Shares for $1.96 million were sold by Nicholson John. On Monday, May 15 CHESS ROBERT sold $98,950 worth of Nektar Therapeutics (NASDAQ:NKTR) or 5,000 shares.

The stock of Nektar Therapeutics (NASDAQ:NKTR) registered an increase of 6.27% in short interest. NKTR’s total short interest was 11.14M shares in July as published by FINRA. Its up 6.27% from 10.48 million shares, reported previously. With 1.32M shares average volume, it will take short sellers 8 days to cover their NKTR’s short positions. The short interest to Nektar Therapeutics’s float is 7.29%.

The stock decreased 0.05% or $0.01 during the last trading session, reaching $20.66. About shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since July 18, 2016 and is uptrending. It has outperformed by 24.82% the S&P500.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need. The company has market cap of $3.18 billion. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It currently has negative earnings. It leverages its chemistry platform to discover and design new drug candidates.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 3 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 7 analyst reports since August 6, 2015 according to SRatingsIntel. Aegis Capital maintained it with “Buy” rating and $2700 target in Monday, June 5 report. Aegis Capital initiated the stock with “Buy” rating in Tuesday, November 8 report. As per Wednesday, August 26, the company rating was downgraded by TheStreet. The stock has “Buy” rating by Roth Capital on Monday, September 21. The rating was maintained by Piper Jaffray with “Overweight” on Thursday, January 7. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, May 30 with “Buy” rating.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics’ (NKTR) CEO Howard Robin On Q1 2017 Results – Earnings …” on May 13, 2017, also Nasdaq.com with their article: “Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options” published on July 06, 2017, Fool.com published: “Here’s What’s Behind Nektar Therapeutics’ 20% Move Higher” on March 02, 2017. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Streetinsider.com and their article: “Nektar Therapeutics (NKTR) Presents New Preclinical Data for NKTR-358” published on July 10, 2017 as well as Marketwatch.com‘s news article titled: “Nektar Therapeutics’ stock jumps after positive results of its pain treatment drug” with publication date: March 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.